Braveheart Bio, Inc. (Ticker: BRVE US) is an American clinical-stage biopharmaceutical company developing therapies for hypertrophic cardiomyopathy and other serious cardiovascular diseases. Incorporated in Delaware and headquartered in San Francisco, the company’s lead candidate, BHB-1893, is being evaluated for obstructive and non-obstructive hypertrophic cardiomyopathy.

Braveheart Bio plans to list on Nasdaq on August 6, 2026. The company is offering 18.8 million shares at an expected price range of $15.00 to $17.00 per share, seeking to raise approximately $300 million at the $16.00 midpoint. Its estimated market capitalization at the offering is around $1.1 billion.

BHB-1893 was discovered and initially developed by China-based Jiangsu Hengrui Pharmaceuticals, from which Braveheart Bio obtained exclusive licensing rights. The company plans to begin a global Phase 3 trial in obstructive hypertrophic cardiomyopathy in the second half of 2026 and another Phase 3 trial in non-obstructive disease in the first half of 2027. Braveheart Bio has not generated product revenue. Goldman Sachs, Jefferies, TD Cowen, Stifel and Cantor are managing the offering.